Skip to main content

Table 2 Participant Clinical Characteristics 1

From: Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity

Participant Characteristics

Total

N = 25*

Phase 1

N = 10

Phase II

N = 15

Doctor(s) seen for lupus1

 Primary care or general doctor

16 (64.0%)

7 (70.0%)

9 (60.0%)

 Lupus specialist or rheumatologist

25 (100%)

10 (100%)

15 (100%)

 Skin doctor or dermatologist

10 (40.0%)

4 (40.0%)

6 (40.0%)

 Kidney doctor or nephrologist

13 (52.0%)

6 (60.0%)

7 (46.7%)

Treatments or medications taken for lupus2

 Hydroxychloroquine (Plaquenil), Quinacrine (Atabrine), or Chloroquine

24 (96.0%)

10 (100%)

14 (93.3%)

 Azathioprine (Imuran)

3 (12.0%)

3 (30.0%)

0 (0%)

 Mycophenolate Mofetil (CellCept), or Mycophenolic acid or MMF

17 (68.0%)

9 (90.0%)

8 (53.3%)

 Tacrolimus, Sirolimus or Cyclosporin

4 (16.0%)

2 (20.0%)

2 (13.3%)

 Cyclophosphamide (Cytoxan)

10 (40.0%)

5 (50.0%)

5 (33.3%)

 Belimumab (Benlysta)

8 (32.0%)

4 (40.0%)

4 (26.7%)

 Methotrexate

9 (36.0%)

2 (20.0%)

7 (46.7%)

 Prednisone or other steroids

23 (92.0%)

10 (100%)

13 (86.7%)

 Other3

8 (32.0%)

1 (10.0%)

7 (46.7%)

Lupus has previously or currently affected kidneys

 Yes

15 (60.0%)

7 (70.0%)

8 (53.3%)

 No

7 (28.0%)

2 (20.0%)

5 (33.3%)

 Don’t know

3 (12.0%)

1 (10.0%)

2 (13.3%)

Currently on dialysis

 Yes

3 (12.0%)

2 (20%)

1 (16.7%)

 No

22 (88.0%)

8 (80.0%)

14 (93.3%)

Experienced being hospitalized for more than 24 h because of a lupus flare

 Yes

19 (76.0%)

9 (90.0%)

10 (66.7%)

 No

6 (24.0%)

1 (10.0%)

5 (33.3%)